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OBJECTIVE—Atherosclerosis is accelerated in subjects with
type 2 diabetes by unknown mechanisms. We identiﬁed tissue
inhibitor of metalloproteinase 3 (TIMP3), the endogenous inhib-
itor of A disintegrin and metalloprotease domain 17 (ADAM17)
and other matrix metalloproteinases (MMPs), as a gene modiﬁer
for insulin resistance and vascular inﬂammation in mice. We
tested its association with atherosclerosis in subjects with type 2
diabetes and identiﬁed Sirtuin 1 (SirT1) as a major regulator of
TIMP3 expression.
RESEARCH DESIGN AND METHODS—We investigated
ADAM10, ADAM17, MMP9, TIMP1, TIMP2, TIMP3, and TIMP4
expression levels in human carotid atherosclerotic plaques (n 
60) from subjects with and without diabetes. Human vascular
smooth muscle cells exposed to several metabolic stimuli were
used to identify regulators of TIMP3 expression. SirT1 small
interference RNA, cDNA, and TIMP3 promoter gene reporter
were used to study SirT1-dependent regulation of TIMP3.
RESULTS—Here, we show that in human carotid atheroscle-
rotic plaques, TIMP3 was signiﬁcantly reduced in subjects with
type 2 diabetes, leading to ADAM17 and MMP9 overactivity.
Reduced expression of TIMP3 was associated in vivo with SirT1
levels. In smooth muscle cells, inhibition of SirT1 activity and
levels reduced TIMP3 expression, whereas SirT1 overexpression
increased TIMP3 promoter activity.
CONCLUSIONS—In atherosclerotic plaques from subjects with
type 2 diabetes, the deregulation of ADAM17 and MMP9 activities
is related to inadequate expression of TIMP3 via SirT1. Studies in
vascular cells conﬁrmed the role of SirT1 in tuning TIMP3
expression. Diabetes 58:2396–2401, 2009
D
iabetes is characterized by accelerated athero-
sclerosis, although molecular mechanisms ex-
plaining this phenomenon are still undeﬁned
(1,2). We and others have shown that chronic
hyperglycemia increases matrix metalloproteinase (MMP)
and A disintegrin and metalloprotease domain (ADAM)
activities providing a potential clue to atherosclerotic
plaque progression, as conﬁrmed by studies using vascu-
lature from subjects with diabetes (3–5). Increased MMP
and ADAM activities may be linked also to unbalanced
expression of endogenous inhibitors called tissue inhibitor
of metalloproteinases (TIMPs) 1–4 (4). We identiﬁed the
deﬁciency of TIMP3 as a link between insulin resistance
and vascular inﬂammation (6–8). Recently, Paigen and
colleagues (9) found Timp3 gene among quantitative trait
loci associated with diabetes and dyslipidemia, identifying
a mutation causing lower gene expression in diabetic
mice. Moreover, Timp3 is among the few genes downregu-
lated in a microarray analysis of pericytes treated with
glycated oxidized LDLs (10). Because TIMP3 uniquely
among TIMPs retains the ability to inhibit shedding en-
zymes such as ADAM17, which are involved in inﬂamma-
tory processes (11), we hypothesized downregulation of
TIMP3 as a hallmark for atherosclerosis in diabetic sub-
jects. We tested this hypothesis in atherosclerotic plaques
from subjects with different degrees of glucose tolerance,
linking TIMP3 expression to activity of deacetylase Sirtuin
1 (SirT1). SirT1 is a deacetylase localized at nuclear levels
acting as transcriptional regulator either on histones or on
transcription factors such as forkhead box class O1
(FoxO1), liver X receptor (LXR), p53, and transcriptional
cofactors such as peroxisome proliferator–activated re-
ceptor coactivator 1 (12). Recently, it has been sug-
gested that loss of SirT1 activity may be associated with
metabolic diseases such as type 2 diabetes and atheroscle-
rosis (13). Several laboratories have shown that SirT1 gain
of function either by genetic manipulation or through
ligand activation may protect from insulin resistance as-
sociated with obesity and from atherosclerosis in experi-
mental disease models (14,15).
However, little is known about SirT1 activity in human
subjects affected by atherosclerosis and diabetes. Our data
reveal a new potential role for TIMP3 and SirT1 in the
atherosclerosis process in subjects with diabetes.
RESEARCH DESIGN AND METHODS
This study included 60 atherosclerotic plaques from normal glucose tolerant
(NGT; n  37) or type 2 diabetic (n  23; according to medical records or oral
glucose tolerance test) subjects in whom carotid endarterectomy for symp-
tomatic disease was performed at Policlinico Tor Vergata University Hospital,
Rome, Italy. Subject characteristics and treatments are described in Table 1.
The study was approved by the ethics committee, and subjects provided
informed written consent for the use of atherosclerotic material for
research use. All procedures were performed according to the Declaration
of Helsinki.
Histological analysis. Carotid plaques were removed en bloc during surgery
to preserve plaque structure entirely. For histology, surgical samples were
ﬁxed for 24 h in 10% buffered formalin immediately upon removal. After
decalciﬁcation, specimens were sectioned transversely every 5 mm and parafﬁn
embedded. Hematoxylin-eosin was performed for morphologic study (4).
Immunohistochemistry was performed on serial 3-m thick sections cut
from parafﬁn blocks of carotid plaques using the following antibodies: 1)
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2396 DIABETES, VOL. 58, OCTOBER 2009 diabetes.diabetesjournals.orgpolyclonal rabbit anti-human TIMP3 antibody (Calbiochem, San Diego, CA),
2) monoclonal anti-CD68 (human macrophage) antibody (DAKO, Glostrup,
Denmark), and 3) monoclonal anti- smooth muscle actin antibody (Europa
Ventana Medical System, Illkirch, France). The primary antibodies were
detected with avidin-biotin-peroxidase complexes (DAKO). All antibodies
were used with positive and negative controls.
Real-time quantitative RT-PCR analysis. Frozen plaque samples were
homogenized using a polytron homogenizer. Total RNA and single-strand
cDNA were obtained as described (7). Real-time PCR RNA expression analysis
of ADAM17, ADAM10, TIMP3, TIMP1, TIMP2, TIMP4, MMP9, and SirT1
(primers available upon request) was performed with ABI PRISM 7000 System
(Applied Biosystems, Foster City, CA) and normalized to 18S rRNA. Each
reaction was carried out in duplicate and analysis performed by 2
Ct method
as described previously (8).
ADAM17 and MMP9 activities. Proteins were extracted as previously
described (4,6–8). ADAM17 activity was determined by the SensoLyte 520
ADAM17 Activity Assay Kit Fluorimetric (AnaSpec, San Jose, CA). MMP9
activity was measured by the Amersham MMP-9 Biotrack Activity Assay
System (GE Healthcare U.K.) according to manufacturer’s instructions. Active
MMP9 was detected through activation of the modiﬁed prodetection enzyme
and subsequent cleavage of its chromogenic peptide substrate. The resultant
color was read at 450 nm in a microplate spectrophotometer (Victor 1420).
LDL preparation, cell culture, and Western blots. LDL preparation (16),
cell culture, and Western blots are described in detail in the online appendix
at http://diabetes.diabetesjournals.org/cgi/content/full/db09-0280/DC1.
Timp3 promoter regulation assay. For Timp3 promoter regulation assay,
coronary artery smooth muscle cells (CASMCs) were transfected with 2 g
Human SirT1 cDNA Clone (RG218134; Origene), 10 ng renilla, and Timp3
Gene Promoter Reporter Vector (LR1034; Panomics) or 2 g TransLucent
Control Vector using primary smooth muscle cells Nucleofector solution with
program A-033 (AMAXA). The luciferase assay was performed with Dual-
Luciferase Reporter Assay System (Promega) according to manufacturer’s
instructions.
Statistical analysis. Statistical analysis was performed using Student’s t test,
one-way ANOVA, and Pearson’s correlation coefﬁcient (r) on SPSS software
program v. 13.0 for Windows. Data are expressed as means  SD. P  0.05
was considered statistically signiﬁcant.
RESULTS
Our data show that in atherosclerotic plaques, among
ADAM10, ADAM17, MMP9, TIMP1, TIMP2, TIMP3, and
TIMP4, only TIMP3 expression was lower in those with
type 2 diabetes than those with NGT (Fig. 1A and B).
Western blot assay conﬁrmed the signiﬁcant decrease of
TIMP3 in subjects with type 2 diabetes (Fig. 1C). Immu-
nohistochemistry completed the link between TIMP3
downregulation and diabetes (Fig. 1D and G, for non–type
2 diabetic and type 2 diabetic subjects, respectively).
Analysis of consecutive sections with anti-CD68 for mac-
rophages and anti- smooth muscle actin for smooth
muscle cells suggested that both cell types are associated
with TIMP3 expression in NGT subjects (Fig. 1E and F for
NGT subjects and Fig. 1H and J for type 2 diabetic
subjects; negative control for antibodies in supplemental
Fig. 1). To verify that the reduction of TIMP3 in athero-
sclerotic plaques resulted in increased ADAM17 and
MMP9 activity, we used a ﬂuorimetric assay. We found
that both ADAM17 and MMP9 activities were higher in
those with type 2 diabetes than in those with NGT (Fig. 1K
and I).
Analysis of clinical characteristics (Table 1) showed
that TIMP3 expression negatively correlates with LDL
cholesterol (r  0.29; P  0.03) and A1C (r  0.31; P 
0.02) but not with sex, age, or pharmacological treatment.
To identify metabolic factors reducing TIMP3 expres-
sion, CASMCs were treated with high glucose (20 mmol/l),
mannitol (osmotic control, 20 mmol/l), hyperinsulinemia
(10
7 M), LDL, oxidized LDL, and glycated LDL (100
ug/ml). Because previous data suggested that LXR regu-
lates TIMP3 expression (17), we used LXR agonists such
as T0901317, 22-s, and 22-r hydroxycholesterol as well as
GW3965. Because LXR is regulated by SirT1 deacetylase
(12), we also used SirT1 inhibitor Sirtinol. Interestingly,
we found that among the various treatments, only high
glucose and Sirtinol signiﬁcantly reduced TIMP3 expres-
sion in CASMC (Fig. 2A).
Treatment of CASMC with Sirtinol determined an in-
creased metalloprotease activity as measured by ADAM17
activity assay (Fig. 2B). Sirtinol and high glucose signiﬁ-
cantly reduced TIMP3 expression also in human umbilical
vein endothelial cells (HUVECs) and monocytic THP1
cells (Fig. 2C). Analysis of CASMC, HUVEC, and THP1
revealed that high glucose signiﬁcantly reduced SirT1
expression (Fig. 2D) in CASMC and THP1 with a trend also
in HUVEC. SirT1 expression was signiﬁcantly reduced in
atherosclerotic plaques from subjects with type 2 diabetes
compared with those from NGT subjects (Fig. 2E), and we
observed that TIMP3 expression positively correlated with
SirT1 expression (r  0.4, P  0.03; Fig. 2F), although
NGT and type 2 diabetic subjects were mixed and there-
fore diabetes may represent a confounding factor. To
conﬁrm a direct role of SirT1 in regulating TIMP3 expres-
sion, we used a small interference RNA approach. Knock-
down of SirT1 in CASMC resulted in marked reduction of
TIMP3 expression but not TIMP1, TIMP2, TIMP4,
ADAM10, ADAM17,o rMMP9 (Fig. 3A); a similar effect
was observed in HUVEC and THP1 cells (Fig. 3B). To
substantiate SirT1 effects on TIMP3, CASMC were co-
transfected with human SirT1 cDNA and Timp3 promoter
luciferase reporter vector, conﬁrming that SirT1 positively
modulates TIMP3 expression (Fig. 3C). Finally, in CASMC,
HUVEC, and THP1 we found that SirT1 overexpression
prevented the reduction of TIMP3 expression determined
by high glucose (Fig. 3D).
DISCUSSION
We recently observed that TIMP3 deﬁciency is necessary
to develop fatty streaks characterized by macrophage
inﬁltrate using the insulin receptor heterozygous mouse
TABLE 1
Clinical data of patients subjected to carotid endarterectomy
NGT
Type 2
diabetes
n 37 23
Sex (men/women) 25/12 14/9
Age (years) 71.0  6.6 70.6  8.9
BMI (kg/m
2) 25.3  3.9 24.1  4.8
Hypertension (yes/no) 29/8 20/3
Antihypertensive drugs
(yes/no) 23/14 15/8
Antiaggregant drugs (yes/no) 35/2 22/1
Statins (yes/no) 25/12 15/8
Total cholesterol (mg/dl) 188.9  31.0 192.35  36.86
HDL cholesterol (mg/dl) 45.32  10.2 43.3  9.6
LDL cholesterol (mg/dl) 115.7  24.6 122.18  28.1
Triglycerides (mg/dl) 125.69  62.26 139.13  72.04
A1C (%) 5.6  0.2 7.2  1.6*
Fasting plasma glucose
(mg/dl) 89.7  12.0 126.9  51†
Fasting plasma insulin
(U/ml) 7.38  5.59 12.96  3.51
Oral agents/insulin treatment — 15/8
Data are means  SD and n.* P  0.001 by Student’s t test. †P 
0.001 by Student’s t test.
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is demonstrated by the reverse phenotype caused by
TACE deﬁciency in the same mouse model, suggesting
that loss of TIMP3 may favor the development of athero-
sclerotic lesions (8). Whereas other studies on models
such as ApoE and LDL receptor knockout are necessary to
fully characterize the role of TIMP3 in the progression of
atherosclerosis under diabetic conditions, here we ana-
lyzed its role in human atherosclerosis accompanied by
diabetes. Our results suggest that subjects with diabetes
exhibit reduction of TIMP3, as well as increased activity of
ADAM17 and MMP9, possibly because of the more intense
oxidative stress caused by hyperglycemia, a known acti-
vator of both the enzymes in a protein kinase C–depen-
dent manner (3,4,18,19). Therefore, our data suggest that
metabolic-dependent reduction in TIMP3 expression may
increase the activity of inﬂammatory and proteolytic en-
zymes, which play a role in atherothrombosis (20,21).
Previous studies showed that TIMP3 expression was
increased in extracts from atheroma compared with non-
atherosclerotic tissue in nondiabetic subjects (22). In view
of our results, TIMP3 reduction is emerging as a speciﬁc
factor in the atherosclerosis process of subjects with
diabetes. Loss of TIMP3 may lead to increased tumor
necrosis factor- and epidermal growth factor receptor
signaling, potentially increasing the inﬂammatory burden
inside the atherosclerotic plaque (6–8). Moreover, loss of
TIMP3 increases MMP9 activity in atherosclerotic plaques,
a feature known to be increased in vasculature from
subjects with type 2 diabetes (5), and may potentially
affect plaque stability in the long term.
The role of TIMPs in diabetic atherothrombosis is still
undeﬁned. Recent data in animal models supported a role
for an imbalanced MMP-to-TIMP ratio favoring increased
NGT
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FIG. 1. TIMP3 is reduced in atherosclerotic plaques of subjects with type 2 diabetes (DM2). ADAM10, ADAM17, and MMP9 (A) as well as TIMPs
(B) expression in NGT (n  37) and type 2 diabetes (n  23) subjects; ***P < 0.001 by one-way ANOVA. C: Western blot using extracellular
matrix extracts from representative NGT (n  2) and type 2 diabetic (n  4) subjects. *P < 0.05 NGT vs. type 2 diabetes by Student’s t test. D–J:
Immunohistochemistry conﬁrmed that TIMP3 is reduced in type 2 diabetic (n  8) versus NGT (n  8) subjects; one representative image is
shown for TIMP3, anti– smooth muscle actin, and CD68 for NGT (D–F;4  magniﬁcation) and type 2 diabetic (G–J;4  magniﬁcation) subjects.
K and I: ADAM17 activity measured by a ﬂuorimetric assay (K) and MMP9 activity measured by a ﬂuorimetric assay (I) are increased in type 2
diabetic (n  23) compared with NGT (n  37) subjects; ***P < 0.001 by Student’s t test for both. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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progression of atherosclerosis (23).
Factors regulating TIMP expression in atherosclerotic
plaques are undeﬁned, although previous data suggested a
role for growth factors such as transcription growth
factor-	 and platelet-derived growth factor (23). However,
the role and regulation of TIMP3 in diabetic vascular
disease has been thus far unexplored. Our data suggested
that TIMP3 is negatively associated with A1C and LDL
cholesterol levels. Exposure of CASMC to different stimuli
linked to gluco- and lipotoxicity revealed that both high
glucose and inhibition of the deacetylase SirT1 led to
reduced TIMP3 expression and activity. SirT1 is emerging
as a master of integrated metabolic response to nutrient
availability (12–15,24). Data from Apolipoprotein E knock-
out mice suggest that overexpression of SirT1 from
endothelial cells may defend against atherosclerosis
progression, although the basic mechanisms remained
undeﬁned. Our results, via knockdown of SirT1 or its
overexpression, conﬁrmed a role for this deacetylase in
the modulation of TIMP3 expression in vascular smooth
muscle cells, and especially monocyte/macrophage. SirT1
controls gene expression through deacetylation of his-
tones and transcription factors; one or both of the two
mechanisms may be involved in regulating TIMP3 expres-
sion. Previous studies using T0901317 compound, an LXR
agonist, suggested that LXR transcription factors regulate
TIMP3 expression (17). In our cell systems we did not
observe an effect of T0901317. However, this may depend
on several factors including different experimental models
and culture conditions. Moreover, SirT1 is a positive
regulator of LXR as well as other transcription factors
potentially involved in TIMP3 expression such as FoxO1
(25). Because SirT1 overexpression is able to rescue
TIMP3 expression in the presence of glucotoxicity, it is
possible that SirT1 affects events linked to de-repression
of TIMP3 promoter via transcription factors such as
FoxO1 or histone deacetylation.
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FIG. 2. Effects of diabetes on TIMP3 expression in vascular cells. A: TIMP3 expression in CASMC treated with various metabolic stimuli: high
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linked to SirT1 identiﬁed in the context of diabetes and
atherosclerosis diseases using human vascular specimens.
Therefore, our results provide further support for the
protective role played by SirT1 against metabolic diseases.
In conclusion, we observed that atherosclerotic plaques
from subjects with impaired glucose metabolism are char-
acterized by TIMP3 deﬁciency and increased metallopro-
teases activity. In vitro studies and clinical correlations
suggested that SirT1 regulates TIMP3 expression, which is
emerging as a speciﬁc factor for the atherosclerosis pro-
cess in diabetes.
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expression in HUVEC and THP1. n  4 for all experiments; ***P < 0.001 by Student’s t test. C: SirT1 cDNA overexpression increased Timp3
promoter activity. n  4 for all experiments; **P < 0.01 by one-way ANOVA. D: SirT1 overexpression increased and prevented loss of TIMP3
expression caused by high glucose (HG; 20 mmol/l) in CASMC, HUVEC, and THP1. n  4 for all experiments; *P < 0.05 by Student’s t test.
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